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Abbreviation 
CSC: cancer stem cell 
DFS: desease free survival 
HCC: hepatocellular carcinoma 
HPC: hepatic progenitor cell 
HR: hazard ratio 
ICC: intrahepatic cholangiocarcinoma 
IHC: immunohistochemistry 
NFT: non tumor liver fibrous tissue 
OS: overall survival 
TMA: tissue microarray 
TS: tumor stroma 
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ABSTRACT 
Background: Recently, we identified a gene signature of intrahepatic choloangiocarcinoma 
(ICC) stroma and demonstrated its clinical relevance for prognosis. The most up-regulated 
genes included EpCAM, a cancer stem cells (CSC) biomarker. We hypothesized that CSC 
biomarkers could predict recurrence of resected ICC.  
Methods: Both functional analysis of the stroma signature previously obtained and 
immunohistochemistry (IHC) of 40 resected ICC were performed. The Relationships between 
the expression of CSC markers and clinicopathological factors including survival were 
assessed by univariate and multivariable analyzes.  
Results: Gene expression profile of the stroma of ICC highlighted embryonic stem cells 
signature. IHC on TMA showed at a protein level the increased expression of CSC 
biomarkers in the stroma of ICC compared to non tumor fibrous liver tissue (NFT). The 
overexpression of EpCAM in the stroma of ICC is an independent risk factor for overall 
(HR=2.6; CI 95% [1.3; 5.1]; p=0.005) and disease free survival (DFS) (HR=2.2; CI 95% [1.2; 
4.2]; p=0.012). In addition, the overexpression of EpCAM in NFT is closely correlated with a 
worst DFS (p=0.035).  
Conclusions: Our findings provide new arguments for a potential role of CSC on ICC 
progression supporting the idea that targeting CSC biomarkers might represent a promise 
personalized treatment. 
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INTRODUCTION 
 
Intrahepatic cholangiocarcinoma (ICC) is considered to be a therapeutic challenge and a 
public health issue. Indeed, while ICC incidence is increasing in all western countries[1], 
complete surgical resection is currently the only available curative treatment. After surgery, 
the 5-year survival rate of patients with ICC remains low ranging between 25% and 35% in 
most of series [2,3]. This poor prognosis is related to the high recurrence rate, especially 
during the first year after liver resection. Recently, we showed that ICC recurrences occurred 
in about half of the patients after surgery with curative intent, frequently during the first year 
and usually in the remnant liver only [4]. This major early recurrence rate as well as the high 
rate of patients diagnosed with satellite nodes in both lobes, suggests that ICC is a 
disseminating parenchymal liver disease. The genomics and molecular mechanisms involved 
in the onset and progression of ICC are poorly documented. Many arguments based on both 
experimental data and the expression of specific markers indicated that ICC may originate 
from cancer stems cells (CSC) or hepatic progenitor cells (HPC)[5]. CSC share functional 
characteristics with normal stem cells including the potential of self-renewal and 
pluripotency. Several reports argue about the role of CSC in tumor progression, tumor relapse 
after treatment and resistance to chemotherapy. Accordingly, Sia et al. demonstrated in a 
genome wide analysis that their subgroup of progressive ICC was associated with a stem-like 
ICC signature [6]. Recently, by combining laser capture microdissection and gene expression 
profiling, a gene signature of the tumor stroma (TS) in ICC have been established and 
associated with a clinical relevance on prognosis[7]. This genomic signature included 1,073 
non-redundant genes that significantly discriminate the TS from non-tumor fibrous tissue. 
Interestingly, the most up-regulated genes in the TS included EpCAM, a well-known marker 
of CSCs in liver tumors [8].  
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To date, the precise functions of CSC in liver tumors remain poorly understood, particularly 
due to the lack of accurate cell surface markers that can be isolated on CSC. However, Ma YC 
et al. showed that the presence of CSCs was associated with a poor histopathologic grade and 
a worse survival including disease-free survival (DFS) in hepatocellular carcinoma (HCC) 
[9].  
 The aim of the study was to determine whether the expression of CSC markers could predict 
recurrence following surgical resection of ICC. 
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METHODS 
Patient Characteristics and Tissue Samples 
Forty patients who underwent liver resection with curative intent for ICC at Rennes-
University hospital between Jan; 1997 and Aug. 2011 were studied. Only mass-forming type 
ICC, as defined by the Liver Cancer Study Group of Japan, were included and analyzed. 
Formalin-fixed paraffin-embedded (FFPE) blocks containing tumor and surrounding non 
tumor liver tissues were retrieved from the archives of the Pathology Institute of Rennes 
University of. The histology of all tumors was reviewed and confirmed by 2 experienced 
pathologists and classified according to UICC 7ed. Clinical features were obtained from 
hospital charts. Data were collected on demographics (age, gender, body mass index), viral 
status (HBV and HCV) and the presence of an underlying liver disease. After resection, the 
follow-up protocol included a clinical examination and a computed tomography scan every 3 
months during 2 years, then every six months thereafter. The end of the follow-up was set 
between January 1.2013 and Mars 1.2013, or at the time of death. The study protocol fulfilled 
national laws and regulations and was approved by the local ethics committee. 
Data Mining of ICC RNA Profiles  
RNA analysis was made by using the gene expression profiles that we established previously 
from the micro dissected stroma of human ICC or fibrous tissue in the adjacent non-tumor 
liver tissue [10]. The full expression dataset was downloaded from the gene expression 
omnibus (GEO) database (accession number, GSE45001). Gene set enrichment analysis 
(GSEA) was performed by using the Java-tool developed at the Broad Institute (Cambridge, 
MA, USA) as previously described [11]. 
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Tissue Microarray Construction (TMA) 
To reduce the experimental variations and to standardize the results, immunohistochemistry 
(IHC) was made by tissue microarray (TMA). TMA design and construction were performed 
using TMADesigner® software and a Minicore 3® tissue Arrayer (Excilone, VICQ France) 
as previously described [10]. Briefly, after a hematoxylin-eosin staining, 3 representative 
areas of stroma from each ICC (TS) and of fibrous tissue from portal tracts areas in the 
surrounding non tumor liver (NFT) were selected by an experienced pathologist (BT) and 
were punched with a cylinder of 1mm diameter before transferred to a TMA block. Thus, 
each tissue block (T and NT) was represented by three independent spots in the TMA. 
Subsequently, immunohistochemical studies were performed on 4 µm tissue sections of 
TMAs. 
Immunostaining for EpCAM, CD44 and CD133 
IHC was performed for CSC markers (EpCAM, CD44 and CD133). As described previously, 
4 µm tissue sections of the TMAs were deparaffinised and immunostained using an 
automated Discovery XT immunostaining device (Ventana Medical System, Tuckson, AZ, 
USA). The following primary monoclonal anti-mouse antibodies were used: EpCAM (1/50, 
eBiosciences, San Diego, CA), CD44 (1/200, ProMab Biotechnologies, Richmond, CA) and 
CD133 (1/200, ProMab Biotechnologies, Richmond, CA). Detection was performed using a 
streptavidin-biotin-peroxidase kit (OmniMap, Biotin-free DAB detection Systems, Ventana 
Medical System). Staining results were independently scored by experienced pathologist (BT) 
in a blind manner. Staining intensity in the stroma was scored as follows: negative (0), mild 
(1), moderate (2), or strong (3). Given that each stromal sample was represented in triplicate, 
the sum of the three values was calculated to obtain a score ranging from 0 to 9. This score 
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was finally categorized into 4 groups to optimize the statistical analysis and to be expandable 
for: 0 (score 0-1), 1 (score 2-3), 2 (score 4-7) and 3 (score 8-9). 
 
 
Statistical Analysis 
Differences in protein expression TS vs. NFT were evaluated by chi-squared test. 
Relationships between protein expression and clinical parameters were evaluated by chi-
squared or Fisher’s exact probability test for categorical variables and using the analysis of 
variance for numerical variables. The Kaplan-Meier method was used to estimate the overall 
(OS) and disease-free survival (DFS) and group differences were analyzed with the log-rank 
test. Univariate and multivariate Cox regression models for the hazards of OS and DFS 
mortality were used to evaluate the effect of protein expression. The most suited Cox model 
was selected using a stepwise regression, selecting variables based on the AIC. P<0.05 was 
considered statistically significant. Statistical analysis was performed with R (version 2.15.1). 
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RESULTS 
Clinicopathological Features of Patients 
Clinicopathological features of patients are reported in table 1. The median age at time of 
surgery was 64.8± 8.8 years. A full follow-up period was available for all patients with a 
mean of 38.7 months (ranging from 2 to 118 months). This cohort represents ICC cases 
encountered in clinical practice, particularly with an even distribution according to the UICC 
7ed classification (37.5%, 30 %, 25%, and 7.5% for stage I, II, III, and IV respectively). 
Among the 40 patients, a recurrence occurred in about half of cases during the follow-up 
period. 
The Stroma of ICC Exhibits CSC Gene Signatures  
A supervised analysis of gene expression profiles that we established previously from 
microdissected ICC tissues demonstrated that the expression of EpCAM was significantly 
increased in the stroma of ICC compared to fibrous tissue in the NT surrounding tissue 
(p<0.05). No significant difference was observed for CD44 and CD133 mRNA levels (Figure 
1A). Data mining of the full dataset by GSEA demonstrated that gene signatures associated 
with embryonic stem cells[12] were significantly enriched in the gene expression profiles of 
the stroma of ICC (normalized enrichment scores, NES >1.5; p<0.05). (Figure 1B) 
 
Immunohistochemistry on TMA Confirmed at a Protein Level the Overexpression of CSC 
Markers in the Stroma of ICC 
Immunostaining on TMA are showed in supplementary figure 1. As reported in figure 1C, a 
significant overexpression of CSC markers in tumor stroma was found in comparison with 
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fibrous areas in the non tumor surrounding liver. The p values corresponding to the 
differential expression of EpCAM, CD44 and CD133 were <0.001, <0.001 and 0.0284 
respectively.  
 
Stromal Expression of EpCAM is an Independent Factor of Prognosis 
Univariate and multivariable analyses of risk factors influencing OS and DFS are reported in 
Tables 2 and 3. Among the 15 variables assessed by the univariate analysis, an age over 65 
years (p=0.029), intrahepatic satellite nodules (p=0.021), CD44 stromal staining (p<0.001) 
and EpCAM stromal staining (p=0.007) were significantly associated with OS. Regarding 
DFS, the univariate analysis showed that tumor size over 50 millimeters (p=0.023), AJCC 
classification (p=0.001), intrahepatic satellite nodules (p=0.021), microvascular invasion 
(p=0.023), perineural infiltration (p=0.004), capsular disruption (p=0.017), CD44 stromal 
staining (p=0.004) and EpCAM surrounding non tumor fibrous tissue staining (p=0.035) were 
significant. 
OS and DFS curves according to EpCAM and CD44 staining are shown in Figures 2 and 
supplementary figure 2 respectively. 
In multivariable analysis, intrahepatic satellite nodules (Hazard ratio [HR] 4.5; confidence 
interval [CI] 95% [1.5; 13.4]; p=0.008) and EpCAM stromal staining (HR=2.6; CI 95% [1.3; 
5.1]; p=0.005) remained significant independent risk factors for reduced OS. Independent risk 
factors of reduced DFS included intrahepatic satellite nodules (HR=3.4; CI 95% [1.2; 9.7]; 
p=0.026), microvascular invasion (HR=2.7; CI 95% [1.2; 6.2]; p=0.016) and EpCAM stromal 
staining (HR=2.2; CI 95% [1.2; 4.2]; p=0.012). 
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These results highlighted the correlation between the overexpression of CSC markers and 
recurrence in ICC.    
DISCUSSION 
 
Intrahepatic cholangiocarcinoma remains characterized by a poor prognosis due to its high 
rate of recurrence and metastasis after liver resection with curative intent. While several 
studies have investigated the prognostic value of clinical and histological factors such as age, 
lymph nodes status, perineural or vascular invasion, margin thickness and the presence of 
intrahepatic satellite nodes, but few had focused on immunohistological factors. The results of 
the present study highlight the potential relationship between the expression of CSC 
biomarkers and the recurrence and poor prognosis of resected ICC. Thus, CSC biomarkers 
expression was found significantly higher in tumor stroma of ICC than in surrounding fibrous 
non liver tissue, as previously reported [13]. Univariate analysis revealed that the 
overexpression of CD44 and EpCAM in tumor stroma was associated with worse OS and 
DFS. Multivariable analysis confirmed that EpCAM overexpression in tumor stroma was an 
independent risk factor of poor OS and DFS. Interestingly, the marked staining of EpCAM in 
the surrounding non-tumor fibrous tissue was also significantly associated with a reduced 
DFS. 
In the early 2000s, the concept of CSC role in tumorigenesis and in cell spreading has been 
emerged[14]. Experimental evidences suggested that HCC and ICC may derive from common 
hepatic progenitor cells (HPCs) or oval cells [5,15,16]. HPCs are located in the smallest and 
most peripheral branches of the biliary tree; the ductules and the canals of Hering at the 
interface between the parenchyma and the portal tract mesenchyme [17]. The activation of 
HPC compartment can give rise to ductular reactions (DR) as a response to liver damage, 
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which is correlated to the degree of inflammation and fibrosis in many chronic liver diseases. 
Recently, Cai et al. demonstrated that DR/HPCs activation in non-tumor tissue contribute on 
the risk of recurrence of hepatocholangiocarcinoma (CHC) after curative resection [18]. 
Similarly, Coulouarn et al. showed by a genome-wide transcriptionnal analysis that this 
particular of mixed tumor exhibits stem/progenitor features associated with poor 
prognosis[19].  
Several recent reports described a specific niche into the stroma where CSC are located 
[20,21] . The Current evidence revealed that the tumor niche has a pivotal role in controlling 
cancer homeostasis and progression. In ICC, CSCs are supposed to be generated through the 
genetic alteration of hepatic stem cells (HSCs), HPCs and probably from cholangiocytes 
themselves[22]. CSCs are identified through the presence of specific cell surface markers. 
The most specific currently described CSC biomarkers in cholangiocarcinoma include 
CD133/prominin-1[23], CD44[24] and EpCAM[25]. Wang et al. demonstrated that 
CD44
+
CD24
+
EpCAM
+ 
cells isolated from extrahepatic cholangiocarcinoma xenografts in 
NOD/SCID mice exhibit a higher tumorigenic potential compared with CD44
-
CD24
-
EpCAM
- 
cells[26].  
The present work provides additional arguments to the hypothesis of the pivotal role of CSC 
in ICC recurrence. Indeed, we showed a close correlation between DFS and the expression of 
CSC markers in the tumor stroma of resected ICCs. Overexpression of EpCAM in the 
surrounding non tumor fibrous tissue was also associated with a reduced DFS, supporting the 
hypothesis that the presence of CSC in the remnant liver after surgery may contribute on the 
high rate of early intrahepatic recurrence. In addition, the presence of CSC may explain the 
ineffectiveness of the current chemotherapy regiment (CT). In fact, conventional CT is 
efficient on differentiated cells which form the main mass of the tumor, though it fails on 
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CSC[21] . Therefore, a combinations of conventional CT and specific treatment targeting 
CSCs, e.g. through specific cell surface markers might represent a promising strategy to 
prevent ICC spreading and relapse after surgery. Different approaches could be considered to 
reverse the drug resistance nature of ICC tumors, including the modulation of the crosstalk 
between CSC and the tumor niche. A recent study revealed that RNA-based blockage of 
EpCAM in HSC and HPC led to a decrease in the invasiveness of HCC cell lines [27]. 
Monoclonal antibodies against EpCAM are now available and were demonstrated to be 
effective in several solid tumors, namely prostatic carcinoma [28], uterine papillary carcinoma 
and pancreatic carcinoma[29]. Among the anti-EpCAM antibodies, adecatumumab (MT201) 
is a safe promising fully human antibody with a long half-life, well tolerated by patients [30].  
A limitation of the present work is linked to the small size of the study group, and further 
studies are needed to confirm the results. Furthermore, EpCAM is a surface biomarker of 
CSC, but also known to be as a marker widely associated with the epithelial to mesenchymal 
transition which could partly explain its role in ICC aggressiveness.  
In conclusion, the present study suggests a potential role of CSC in the aggressiveness and 
recurrence of ICC. In addition, we propose EpCAM as a new independent risk factor for 
poorest survival which can be performed in routine immunohistochemistry. Further studies 
are mandatory to validate EpCAM as a biomarker for adapted therapies of ICC, including 
surgical resection of the tumor and the follow-up of patients. In fact, patients with high 
expression of EpCAM might benefit from an adjuvant treatment using a combination of CT 
regimens and targeted biotherapy, such as the neutralizing antibodies adecatunumab, which is 
an appealing strategy and to be explored in the near future. 
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FIGURE LEGENDS 
 
 
 
Figure1. Functional analysis of the ICC stroma signature. (A) Evaluation of relative mRNA 
level of selected genes demonstrated a significant increased in the expression of EpCAM in 
the stroma of ICC compared to the surrounding  non tumor liver tissue. The p-value was 
determined using a 2-tailed Student’s t-test. (B) Gene set enrichment analysis (GSEA) 
demonstrated that gene signatures associated with embryonic stem cells were significantly 
enriched in the gene expression profiles of the stroma of ICC (normalized enrichment scores, 
NES >1.5; p<0.05). (C) Immunohistological analysis of Epcam, CD44 and CD133 protein 
expression in TS and NFT. 
 
 
 
 
Figure2. Kaplan-Meier curves and log-rank analysis of survival according to expression of 
EpCAM. (A) Overall survival according to expression of EpCAM in the stroma of ICC. (B) 
Disease free survival according to expression of EpCAM in the stroma of ICC. (C) Disease 
free survival according to expression of EpCAM in the surrounding non tumor fibrous tissue 
 
 
Supplementary Figure1. Immunohistochemical staining of EpCAM and CD44  in tissue 
microarray. (A) EpCAM staining score mild in tumor stroma (TS). (B) EpCAM staining score 
strong in TS. (C) EpCAM staining score mild in non tumor fibrous tissue (NFT). (D) EpCAM 
staining score moderate in NFT.  
 
Supplementary Figure2. Kaplan-Meier curves and log-rank analysis of survival according to 
expression of CD44. (A) Overall survival according to expression of CD44 in the stroma of 
ICC. (B) Disease free survival according to expression of CD44 in the stroma of ICC 
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